Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT04330664
Official study title

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Study summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMRTX849 and TNO155

The study team can explain what participation involves.

Who it may be forKRAS · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 4, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?17 U.S. locations

Locations may change over time.

Who runs it?Mirati Therapeutics Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Mirati Therapeutics Inc.
Interventions being studied
Drug: MRTX849; Drug: TNO155
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Metastatic or stage IV→
Biomarkers
KRAS→
Treatment approach
Targeted therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
  • Unresectable or metastatic disease
  • No available treatment with curative intent
  • Adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • Other active cancer
  • Cardiac abnormalities

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Local Institution - 002-805Los Angeles, California
  • Local Institution - 002-803Orange, California
  • Local Institution - 002-828Chicago, Illinois
  • Local Institution - 002-942Wichita, Kansas
  • Local Institution - 002-804Boston, Massachusetts
  • Local Institution - 002-808Boston, Massachusetts
  • Local Institution - 002-811Novi, Michigan
  • Local Institution - 002-809 DCity of Saint Peters, Missouri
  • Local Institution - 002-809 BCreve Coeur, Missouri
  • Local Institution - 002-809 ASt Louis, Missouri
  • Local Institution - 002-809 CSt Louis, Missouri
  • Local Institution - 002-809St Louis, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 4, 2025. Always confirm current availability with the study team.

View original record ↗